Meeting
2023 ASCO Genitourinary Cancers Symposium
Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: Long-term data from two randomized trials.
Presenter
Abdenour Nabid, FRCPC
Centre Hospitalier Universitaire de Sherbrooke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
General Session
Session Title
Controversies in Androgen Deprivation and Testosterone Supplementation for Patients With Prostate Cancer
Track
Prostate Cancer
Sub Track
Other
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 300)
DOI
10.1200/JCO.2023.41.6_suppl.300
Abstract #
300
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Quality Care Symposium
Moderated Panel Discussion with Drs. Pinheiro, Winkfield, Gaufberg, Ramkumar, Reeder-Hayes, Taparra, and Xiang
Speaker: Panel Discussion
Videos & Slides
2021 ASCO Annual Meeting
Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.
Speaker: Anthony Victor D'Amico, MD, PhD
Videos & Slides
2021 Genitourinary Cancers Symposium
Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.
Speaker: Jonathan David Tward, MD, PhD
Videos & Slides
2020 ASCO Virtual Scientific Program
Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).
Speaker: Fernando C. Maluf, MD